Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab

PHASE2UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Lapatinib

lapatinib 1000mg, once daily

DRUG

Vinorelbine

Vinorelbine 20mg/m2, D1 and D8, every 3 weeks

Trial Locations (1)

410-769

RECRUITING

National Cancer Center, Goyang-si

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Asan Medical Center

OTHER

collaborator

Chung-Ang University

OTHER

collaborator

Korea University Anam Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

lead

National Cancer Center, Korea

OTHER_GOV

NCT01730677 - Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab | Biotech Hunter | Biotech Hunter